



June 16, 2005

FILE COPY

Mark Pohl, Esq.
Pharmaceutical Patent Attorneys, LLC
55 Madison Avenue, 4th Floor
Morristown, NJ 07960-7397

Dear Mr. Pohl:

Your petition requesting the Food and Drug Administration to make a determination that lamotrigene oral tablets in 50 mg and 250 mg strengths were not withdrawn due to safety or efficacy concerns, was received by this office on 06/15/2005. It was assigned docket number 2005P-0237/CP1 and it was filed on 06/15/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

2005P-0237

ACK 1